Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study

Mirei Shirakashi, Hajime Yoshifuji, Yuzo Kodama, Tsutomu Chiba, Motohisa Yamamoto, Hiroki Takahashi, Kazushige Uchida, Kazuichi Okazaki, Tetsuya Ito, Shigeyuki Kawa, Kazunori Yamada, Mitsuhiro Kawano, Shintaro Hirata, Yoshiya Tanaka, Masafumi Moriyama, Seiji Nakamura, Terumi Kamisawa, Shoko Matsui, Hiroto Tsuboi, Takayuki SumidaMotoko Shibata, Hiroshi Goto, Yasuharu Sato, Tadashi Yoshino, Tsuneyo Mimori

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Glucocorticoids (GC) are effective for treating IgG4-related disease (IgG4-RD); however, relapse is often observed. We conducted a retrospective multicentre study to investigate risk factors in GC regimens associated with relapses of IgG4-RD. Data on 166 patients with definitive IgG4-RD diagnosis were collected from 12 institutions. Comprehensive surveillance of clinical backgrounds and GC regimens as well as multivariate analysis of factors associated with treatment responses and relapses was performed. To determine the initial maximal GC dose, the patients were stratified into three groups depending on the initial prednisolone (PSL) dosage: <0.39, 0.4–0.69 and >0.7 mg/kg/day. The multivariate analysis extracted the disease duration and reduction speed of initial GC dose. Patients treated with initial GC <0.39 or >0.7 mg/kg/day of PSL showed higher relapse rates than those treated with 0.4–0.69 mg/kg/day. The relapse rates were significantly higher in patients with fast reduction of the initial dose (>0.4 mg/day) than in patients with slow reduction (<0.4 mg/day). To avoid relapse, 0.4–0.69 mg/kg/day of initial PSL with slow reduction speed (<0.4 mg/day) is needed in the early treatment of IgG4-RD.

Original languageEnglish
Article number10262
JournalScientific reports
Volume8
Issue number1
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Glucocorticoids
Multicenter Studies
Immunoglobulin G
Recurrence
Prednisolone
Therapeutics
Multivariate Analysis
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • General

Cite this

Shirakashi, M., Yoshifuji, H., Kodama, Y., Chiba, T., Yamamoto, M., Takahashi, H., ... Mimori, T. (2018). Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Scientific reports, 8(1), [10262]. https://doi.org/10.1038/s41598-018-28405-x

Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease : a multicentre study. / Shirakashi, Mirei; Yoshifuji, Hajime; Kodama, Yuzo; Chiba, Tsutomu; Yamamoto, Motohisa; Takahashi, Hiroki; Uchida, Kazushige; Okazaki, Kazuichi; Ito, Tetsuya; Kawa, Shigeyuki; Yamada, Kazunori; Kawano, Mitsuhiro; Hirata, Shintaro; Tanaka, Yoshiya; Moriyama, Masafumi; Nakamura, Seiji; Kamisawa, Terumi; Matsui, Shoko; Tsuboi, Hiroto; Sumida, Takayuki; Shibata, Motoko; Goto, Hiroshi; Sato, Yasuharu; Yoshino, Tadashi; Mimori, Tsuneyo.

In: Scientific reports, Vol. 8, No. 1, 10262, 01.12.2018.

Research output: Contribution to journalArticle

Shirakashi, M, Yoshifuji, H, Kodama, Y, Chiba, T, Yamamoto, M, Takahashi, H, Uchida, K, Okazaki, K, Ito, T, Kawa, S, Yamada, K, Kawano, M, Hirata, S, Tanaka, Y, Moriyama, M, Nakamura, S, Kamisawa, T, Matsui, S, Tsuboi, H, Sumida, T, Shibata, M, Goto, H, Sato, Y, Yoshino, T & Mimori, T 2018, 'Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study', Scientific reports, vol. 8, no. 1, 10262. https://doi.org/10.1038/s41598-018-28405-x
Shirakashi, Mirei ; Yoshifuji, Hajime ; Kodama, Yuzo ; Chiba, Tsutomu ; Yamamoto, Motohisa ; Takahashi, Hiroki ; Uchida, Kazushige ; Okazaki, Kazuichi ; Ito, Tetsuya ; Kawa, Shigeyuki ; Yamada, Kazunori ; Kawano, Mitsuhiro ; Hirata, Shintaro ; Tanaka, Yoshiya ; Moriyama, Masafumi ; Nakamura, Seiji ; Kamisawa, Terumi ; Matsui, Shoko ; Tsuboi, Hiroto ; Sumida, Takayuki ; Shibata, Motoko ; Goto, Hiroshi ; Sato, Yasuharu ; Yoshino, Tadashi ; Mimori, Tsuneyo. / Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease : a multicentre study. In: Scientific reports. 2018 ; Vol. 8, No. 1.
@article{59f2971b537b43a0bb30ffac04953d87,
title = "Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study",
abstract = "Glucocorticoids (GC) are effective for treating IgG4-related disease (IgG4-RD); however, relapse is often observed. We conducted a retrospective multicentre study to investigate risk factors in GC regimens associated with relapses of IgG4-RD. Data on 166 patients with definitive IgG4-RD diagnosis were collected from 12 institutions. Comprehensive surveillance of clinical backgrounds and GC regimens as well as multivariate analysis of factors associated with treatment responses and relapses was performed. To determine the initial maximal GC dose, the patients were stratified into three groups depending on the initial prednisolone (PSL) dosage: <0.39, 0.4–0.69 and >0.7 mg/kg/day. The multivariate analysis extracted the disease duration and reduction speed of initial GC dose. Patients treated with initial GC <0.39 or >0.7 mg/kg/day of PSL showed higher relapse rates than those treated with 0.4–0.69 mg/kg/day. The relapse rates were significantly higher in patients with fast reduction of the initial dose (>0.4 mg/day) than in patients with slow reduction (<0.4 mg/day). To avoid relapse, 0.4–0.69 mg/kg/day of initial PSL with slow reduction speed (<0.4 mg/day) is needed in the early treatment of IgG4-RD.",
author = "Mirei Shirakashi and Hajime Yoshifuji and Yuzo Kodama and Tsutomu Chiba and Motohisa Yamamoto and Hiroki Takahashi and Kazushige Uchida and Kazuichi Okazaki and Tetsuya Ito and Shigeyuki Kawa and Kazunori Yamada and Mitsuhiro Kawano and Shintaro Hirata and Yoshiya Tanaka and Masafumi Moriyama and Seiji Nakamura and Terumi Kamisawa and Shoko Matsui and Hiroto Tsuboi and Takayuki Sumida and Motoko Shibata and Hiroshi Goto and Yasuharu Sato and Tadashi Yoshino and Tsuneyo Mimori",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-28405-x",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease

T2 - a multicentre study

AU - Shirakashi, Mirei

AU - Yoshifuji, Hajime

AU - Kodama, Yuzo

AU - Chiba, Tsutomu

AU - Yamamoto, Motohisa

AU - Takahashi, Hiroki

AU - Uchida, Kazushige

AU - Okazaki, Kazuichi

AU - Ito, Tetsuya

AU - Kawa, Shigeyuki

AU - Yamada, Kazunori

AU - Kawano, Mitsuhiro

AU - Hirata, Shintaro

AU - Tanaka, Yoshiya

AU - Moriyama, Masafumi

AU - Nakamura, Seiji

AU - Kamisawa, Terumi

AU - Matsui, Shoko

AU - Tsuboi, Hiroto

AU - Sumida, Takayuki

AU - Shibata, Motoko

AU - Goto, Hiroshi

AU - Sato, Yasuharu

AU - Yoshino, Tadashi

AU - Mimori, Tsuneyo

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Glucocorticoids (GC) are effective for treating IgG4-related disease (IgG4-RD); however, relapse is often observed. We conducted a retrospective multicentre study to investigate risk factors in GC regimens associated with relapses of IgG4-RD. Data on 166 patients with definitive IgG4-RD diagnosis were collected from 12 institutions. Comprehensive surveillance of clinical backgrounds and GC regimens as well as multivariate analysis of factors associated with treatment responses and relapses was performed. To determine the initial maximal GC dose, the patients were stratified into three groups depending on the initial prednisolone (PSL) dosage: <0.39, 0.4–0.69 and >0.7 mg/kg/day. The multivariate analysis extracted the disease duration and reduction speed of initial GC dose. Patients treated with initial GC <0.39 or >0.7 mg/kg/day of PSL showed higher relapse rates than those treated with 0.4–0.69 mg/kg/day. The relapse rates were significantly higher in patients with fast reduction of the initial dose (>0.4 mg/day) than in patients with slow reduction (<0.4 mg/day). To avoid relapse, 0.4–0.69 mg/kg/day of initial PSL with slow reduction speed (<0.4 mg/day) is needed in the early treatment of IgG4-RD.

AB - Glucocorticoids (GC) are effective for treating IgG4-related disease (IgG4-RD); however, relapse is often observed. We conducted a retrospective multicentre study to investigate risk factors in GC regimens associated with relapses of IgG4-RD. Data on 166 patients with definitive IgG4-RD diagnosis were collected from 12 institutions. Comprehensive surveillance of clinical backgrounds and GC regimens as well as multivariate analysis of factors associated with treatment responses and relapses was performed. To determine the initial maximal GC dose, the patients were stratified into three groups depending on the initial prednisolone (PSL) dosage: <0.39, 0.4–0.69 and >0.7 mg/kg/day. The multivariate analysis extracted the disease duration and reduction speed of initial GC dose. Patients treated with initial GC <0.39 or >0.7 mg/kg/day of PSL showed higher relapse rates than those treated with 0.4–0.69 mg/kg/day. The relapse rates were significantly higher in patients with fast reduction of the initial dose (>0.4 mg/day) than in patients with slow reduction (<0.4 mg/day). To avoid relapse, 0.4–0.69 mg/kg/day of initial PSL with slow reduction speed (<0.4 mg/day) is needed in the early treatment of IgG4-RD.

UR - http://www.scopus.com/inward/record.url?scp=85058710215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058710215&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-28405-x

DO - 10.1038/s41598-018-28405-x

M3 - Article

C2 - 29980706

AN - SCOPUS:85058710215

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 10262

ER -